Nanexa AB is focused on the development of long-acting injectable pharmaceuticals through its proprietary PharmaShell® technology. This innovative drug delivery system allows for the creation of next-generation injectable medications with a high drug load, manufactured with atomic layer precision. The company operates a unique pilot facility and laboratories in Uppsala, where it advances both its own product projects and collaborative initiatives with other pharmaceutical companies, including partnerships with major players like AstraZeneca.

The PharmaShell® system is designed to enable sustained release formulations, exemplified by Nanexa's recent Phase I study of NEX-22, a long-acting GLP-1 analogue for the treatment of type 2 diabetes. This formulation allows for monthly dosing, showcasing the potential of the PharmaShell® technology to improve patient compliance and therapeutic outcomes. Nanexa's commitment to innovation in drug delivery positions it as a leader in the pharmaceutical industry, aiming to revolutionize how injectable medications are developed and administered.

Sweden

Nanexa AB is a drug delivery company that focuses on the development of PharmaShell®, a new and pioneering drug delivery system that is considered to have great potential in a number of substance types and indication areas. Within the framework of PharmaShell®, Nanexa develops its own projects and has collaborative agreements with several pharmaceutical companies, including AstraZeneca.

Nanexa AB

Company Details